This fact could be explained because our cohort of patients include only high-risk MDS and sAML, which have been highly associated with complex karyotypes (46% in our series) and it is also well known that TP53 mutations are enriched in patients with these cytogenetic characteristics [22]. The gene discussed is TP53; the disease is myelodysplastic syndrome.